Role of probiotics in inflammatory bowel disease and intestinal infections

Bibliography

• BENGMARK S: Bacteria for optimal health. Nutrition (2000) 16:611–615.
   PubMedGoogle Scholar
• SIMON GL, GORBACH SL: Intestinal flora in health and disease. Gastroenterology (1984) 86:174–193.
   PubMed Web of Science ®Google Scholar
• METCHNIKOFF E: The Prolongation of Life: Optimistic Studies. Mitchell C (Ed.), William Heinemann, London, UK (1907):161–183.
   Google Scholar
• TISSIER H: Traitement des infections intestinales par la méthode de la fore bactérienne de l'intestin. C. R. Seances Soc. Biol. Fil. (1906) 60:359–361.
   Google Scholar
• LILLY DM, STILLWELL RH: Probiotics: growth promoting factors produced by microorganisms. Science (1965) 47:747–748.
   Google Scholar
• FULLER R: Probiotics in human medicine. Gut (1991) 32:439–442.
   PubMed Web of Science ®Google Scholar
• SCHAAFSMA G: State of the art concerning probiotic strains in milk products. IDF Nutr. News]. (1996) 5:23–24.
   Google Scholar
• LEE YK, SALMINEN S: The coming age of probiotics. Trends Food Sci. Technol (1995) 6:241–245.
   Web of Science ®Google Scholar
• WAGNER ED, WARNER T, ROBERTS L,FARMER J, BALISH E: Colonisation of congenitally immunodeficient mice with probiotic bacteria. Infect. Inunurrol. (1997) 65:3345–3351.
   PubMed Web of Science ®Google Scholar
• SHANAHAN F: Therapeutic manipulation of gut flora. Science (2000) 289:1311–1312.
   PubMed Web of Science ®Google Scholar
• •Interesting review concerning the possibility to treat or prevent IBD through manipulation of gut flora.
   Google Scholar
• SARTOR RB: Enteric microflora in IBD: pathogens or commensals? Inflain. Bowel Dis. (1997) 3:230–235.
   PubMed Web of Science ®Google Scholar
• DUCHMANN R, KAISER I, HERMANN E et al.: Tolerance exist towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Exp. Inunurrol. (1995) 102:104–108.
   Google Scholar
• ••Elegant study confirming the existence of abreakdown of oral tolerance versus intestinal microflora in patients with IBD.
   Google Scholar
• MACPHERSON A, KHOO UY, FORGACS I, PHILPOTT-HOWARD J, BJARNASON I: Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut (1996) 38:365–375.
   PubMed Web of Science ®Google Scholar
• JANOWITZ HD, CROEN EC, SACHAR DB: The role of the faecal stream in Crohn's disease: an historical and analytic perspective. Inflain. Bowel Dis. (1998) 4:29–39.
   PubMed Web of Science ®Google Scholar
• D'HAENS GR, GEBOES K, PEETERS M, PENNINCKX E RUTGEERS P: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology (1998) 114:262–267.
   PubMed Web of Science ®Google Scholar
• SARTOR RB: Insights into the pathogenesis of inflammatory bowel disease provided by new rodent models of spontaneous colitis. Intim. Bowel Dis. (1995) 1:64–75.
   Google Scholar
• CAMPIERI M, GIONCHETTI P: Probiotics iniInflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology (1999) 116:1246–1249.
   PubMed Web of Science ®Google Scholar
• •Editorial on the potential role of probiotics in IBD therapy.
   Google Scholar
• FABIA R, AR'RAJAB A, JOHANSSON ML et al: Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion (1993) 54:248–255.
   PubMedGoogle Scholar
• FAVIER C, NEUT C, MIZON C, CORTOT A, COLOMBEL JF, MIZON J: Faecal P-D-galactosidase production and bifidobacteria are decreased in Crohn's disease. Dig. Dis. Sci. (1997) 42:817–822.
   PubMed Web of Science ®Google Scholar
• RUSELER-VAN-EMBDEN JGH, SCHOUTEN WR, VAN LIESHOUT LMC: Pouchitis: result of microbial imbalance? Gut (1994) 35:658–64.
   PubMedGoogle Scholar
• FABIA R, AR'RAJAB A, JOHANSSON M-L et al: The effect of exogenous administration of Lactobacillus reuteril R2LC and oat fiber on acetic acid-induced colitis in the rat. Scant/. j Gastroenterol. (1993) 28:155–162.
   PubMedGoogle Scholar
• MAO Y, NOBAEK S, KASRAVI B et al.: The effects of Lactobacillus strains and oat fibre on methotrexate-induced enterocolitis in rats. Gastroenterology (1996) 111:334–344.
   PubMed Web of Science ®Google Scholar
• MADSEN KL, TAVERNINI MM, DOYLE JSG, FEDORAK RN: Lactobacillus sp. prevents development of enterocolitis in interleukin-10 gene-deficient mice. Gastroenterology (1999) 116:1107–1114.
   Google Scholar
• SCHULTZ M, VELTKAMP C, DIELEMAN LA, WYRICK PB, TONKONOGY SL, SARTOR RB: Continuous feeding of Lactobacillus plantarum attenuates established colitis in interleukin-10 deficient mice. Gastroenterology (1998) 114:A1081.
   Web of Science ®Google Scholar
• MALCHOW HA: Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?,./ Clin. Gastroenterol (1997) 25:653–658.
   Google Scholar
• KRUIS W, SCHUTS E, FRIC P, FIXA B, JUDMAIER G, STOLTE M: Double-blind comparison of an oral Escherichia coil preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Titer. (1997) 11:853–858.
   PubMed Web of Science ®Google Scholar
• REMBACKEN BJ, SNELLING AM, HAWKEY P, CHALMERS DM, AXON TR: Non pathogenic Escherichia coil vs. mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (1999) 354:635–639.
   PubMed Web of Science ®Google Scholar
• GUSLANDI M, MEZZI G, SORGHI M etal.: Saccharomyces boulardil in maintenance treatment of Crohn's disease. Dig. Dis. Sci. (2000) 45:1462–1464.
   Google Scholar
• VENTURI A, GIONCHETTI P, RIZZELLO F et al.: Impact on the faecal flora composition of a new probiotic preparation. Preliminary data on maintenance treatment of patients with ulcerative colitis (UC) intolerant or allergic to 5-aminosalicylic acid (5 ASA). Aliment. Pharmacol. Titer. (1999) 13: 1103–1108.
   Google Scholar
• SARTOR RB: Probiotics in chronic pouchitis: restoring luminal microbial balance. Gastroenterology (2000) 119:584–585.
   PubMed Web of Science ®Google Scholar
• ••Very interesting editorial article on thepossible therapeutic role of probiotics in IBD.
   Google Scholar
• GIONCHETTI E RIZZELLO VENTURI A et al: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 119:305–309.
   PubMedGoogle Scholar
• ••Double-blind, placebo-controlled trialshowing a clear benefit for highly concentrated probiotic preparation in maintenance treatment of chronic pouchitis.
   Google Scholar
• GIONCHETTI E RIZZELLO VENTURI A et al: Profilaxis of pouchitis onset with probiotic therapy: a double blind, placebo controlled trial. Gastroenterology (2000) 118:A190 (Abstr.act.
   Google Scholar
• •Double-blind, placebo-controlled trial showing benefit for probiotic treatment in prevention of pouchitis onset during the first year after pouch surgery.
   Google Scholar
• CAMPIERI M, RIZZELLO E VENTURI A et al: Combination of antibiotic and probiotic treatment is efficacious in profilaxis of post-operative recurrence of Crohn's disease: a randomised controlled study vs. mesalazine. Gastroenterology(2000) 118:A781 (Abstr.).
   Google Scholar
• GIONCHETTI E RIZZELLO CIFONE G et al: In vivo effect of a highly concentrated probiotic preparation on IL-10 pelvic ileal-pouch tissue levels. Gastroenterology (1999) 116:A723 (Abstract).
   Google Scholar
• GIONCHETTI E RIZZELLO VENTURI A, CAMPIERI M: Probiotics in infective diarrhoea and inflammatory bowel diseases. I Gastroenter. Hepatol. (2000) 15:489–493.
   PubMedGoogle Scholar
• VANDERHOOF JA: Probiotics and Intestinal Inflammatory Disorders in Infants and Children. j Pediatr. Gastroenterol. Nutrition (2000)30:s34–38.
   PubMedGoogle Scholar
• GUARINO A: Probiotics as adjuntive treatment in cystic fibrosis. Gastroenterology (1999) 116:A885.
   Google Scholar
• MATSUZAKI T: Immunomodulation by treatment with Lactobacillus easel strain Shirota. Intl Food Microbial. (1998) 41:133–140.
   PubMed Web of Science ®Google Scholar
• VANDERHOOF JA, YOUNG RJ: The role of probiotics in the treatment of intestinal infections and inflammation. Curr. Opin. Gastroenterol. (2001) 17:58–62.
   PubMedGoogle Scholar
• LEWIS SJ, FREEDMAN AR: Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment. Pharmacol. Titer. (1998) 12:807–822.
   PubMed Web of Science ®Google Scholar
• BLACK FT, ANDERSON PL, ORSKOV J et al: Prophylactic efficacy of lactobacilli on traveller's diarrhoea. j Travel Med. (1989) 7:333–335.
   Google Scholar
• POCHAPIN MB, ABROMOWITCH M, RAMEY L: Short course antibiotics with probiotics for Clostridium difficile colitis in immunocompromised patients. J Pediatr. Gastroenterol Nutr. (1997) 25:471.
   Google Scholar
• VANDERHOOF JA, WHITNEY DB, ANTONSON DL etal.: Lactobacillus GG in the prevention of antibiotic-associated diarrhoea in children. j Pediatr. (1999) 135:564–568.
   Google Scholar
• ••Large double-blind placebo-controlledstudy showing the efficacy of Lactobacillus GC in prevention of pediatric antibiotic-associated diarrhoea.
   Google Scholar